¹²³I-Meta-iodobenzylguanidine Sympathetic Imaging: Standardization and Application to Neurological Diseases / 전남의대학술지
Chonnam Medical Journal
;
: 145-150, 2016.
Artículo
en Inglés
| WPRIM
| ID: wpr-25334
ABSTRACT
¹²³I-meta-iodobenzylguanidine (MIBG) has become widely applied in Japan since its introduction to clinical cardiology and neurology practice in the 1990s. Neurological studies found decreased cardiac uptake of ¹²³I-MIBG in Lewy-body diseases including Parkinson's disease and dementia with Lewy bodies. Thus, cardiac MIBG uptake is now considered a biomarker of Lewy body diseases. Although scintigraphic images of ¹²³I-MIBG can be visually interpreted, an average count ratio of heart-to-mediastinum (H/M) has commonly served as a semi-quantitative marker of sympathetic activity. Since H/M ratios significantly vary according to acquisition and processing conditions, quality control should be appropriate, and quantitation should be standardized. The threshold H/M ratio for differentiating Lewy-body disease is 2.0-2.1, and was based on standardized H/M ratios to comparable values of medium-energy collimators. Parkinson's disease can be separated from various types of parkinsonian syndromes using cardiac ¹²³I-MIBG, whereas activity is decreased on images of Lewy-body diseases using both ¹²³I-ioflupane for the striatum and ¹²³I-MIBG. Despite being a simple index, the H/M ratio of ¹²³I-MIBG uptake is reproducible and can serve as an effective tool to support a diagnosis of Lewy-body diseases in neurological practice.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Enfermedad de Parkinson
/
Control de Calidad
/
Cardiología
/
Cuerpos de Lewy
/
3-Yodobencilguanidina
/
Trastornos Parkinsonianos
/
Enfermedad por Cuerpos de Lewy
/
Demencia
/
Diagnóstico
/
Japón
Tipo de estudio:
Estudio diagnóstico
País/Región como asunto:
Asia
Idioma:
Inglés
Revista:
Chonnam Medical Journal
Año:
2016
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS